- Home
- HL vs IONS Comparison
HL vs IONS Comparison
Compare HL & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HL | IONS |
|---|---|---|
| Founded | 1891 | 1989 |
| Country | United States | United States |
| Employees | 1865 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 11.9B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | HL | IONS |
|---|---|---|
| Price | $18.68 | $76.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 22 |
| Target Price | $21.13 | ★ $93.36 |
| AVG Volume (30 Days) | ★ 10.4M | 1.6M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | N/A | ★ 21.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.92 | N/A |
| Revenue Next Year | N/A | $77.99 |
| P/E Ratio | $44.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.82 | $31.67 |
| 52 Week High | $34.17 | $86.74 |
Technical Indicators
Market Signals| Indicator | HL | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 56.08 |
| Support Level | $16.53 | $75.66 |
| Resistance Level | $20.87 | $77.08 |
| Average True Range (ATR) | 0.78 | 2.25 |
| MACD | -0.00 | 0.24 |
| Stochastic Oscillator | 49.85 | 76.01 |
Price Performance
Historical ComparisonAbout HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).